Cargando…

The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients

BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Qing, Zhao, Yi-Yang, Zeng, Yu-Qin, Liu, Cong, Cheng, Wei, Deng, Min-Hua, Li, Xin, Ma, Li-Bing, Chen, Yan, Cai, Shan, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143960/
https://www.ncbi.nlm.nih.gov/pubmed/34040367
http://dx.doi.org/10.2147/COPD.S309267
_version_ 1783696861079535616
author Song, Qing
Zhao, Yi-Yang
Zeng, Yu-Qin
Liu, Cong
Cheng, Wei
Deng, Min-Hua
Li, Xin
Ma, Li-Bing
Chen, Yan
Cai, Shan
Chen, Ping
author_facet Song, Qing
Zhao, Yi-Yang
Zeng, Yu-Qin
Liu, Cong
Cheng, Wei
Deng, Min-Hua
Li, Xin
Ma, Li-Bing
Chen, Yan
Cai, Shan
Chen, Ping
author_sort Song, Qing
collection PubMed
description BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) patients. METHODS: For this prospective observational study, stable COPD outpatients were enrolled and divided into Groups A, B, C and D based on GOLD 2017, and followed-up for 18 months. Data on demographics, pulmonary function, COPD assessment test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), exacerbations, mortality and treatments were collected. A post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity <0.70 confirms the presence of airflow limitation. RESULTS: A total of 993 subjects were classified into Groups A (n = 170, 17.1%), B (n = 360, 36.3%), C (n = 122, 12.3%), and D (n = 341, 34.3%). There were significant differences in mMRC, CAT, CCQ, exacerbations and hospitalizations rates among the different groups (P < 0.001). Groups B and D had more severe airflow limitation than Groups A and C (P < 0.05). In the same groups with different severity of airflow limitation, the differences were mainly observed in body mass index, CAT, CCQ and treatment with long-acting muscarinic antagonist (LAMA) and LAMA + long-acting β2-agonist + inhaled corticosteroid (P < 0.05). After 18 months of follow-up, the exacerbations and hospitalizations rates were significantly different among different groups (P < 0.05). However, in the same groups with different airflow limitation severity, the mortality rates and number of exacerbations, hospitalizations and frequent exacerbators showed no differences. CONCLUSION: In the GOLD groups, different severity of airflow limitation had no impact on future exacerbations and mortality rate. It implies that pulmonary function is not a good indicator for predicting exacerbation.
format Online
Article
Text
id pubmed-8143960
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81439602021-05-25 The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients Song, Qing Zhao, Yi-Yang Zeng, Yu-Qin Liu, Cong Cheng, Wei Deng, Min-Hua Li, Xin Ma, Li-Bing Chen, Yan Cai, Shan Chen, Ping Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) patients. METHODS: For this prospective observational study, stable COPD outpatients were enrolled and divided into Groups A, B, C and D based on GOLD 2017, and followed-up for 18 months. Data on demographics, pulmonary function, COPD assessment test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), exacerbations, mortality and treatments were collected. A post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity <0.70 confirms the presence of airflow limitation. RESULTS: A total of 993 subjects were classified into Groups A (n = 170, 17.1%), B (n = 360, 36.3%), C (n = 122, 12.3%), and D (n = 341, 34.3%). There were significant differences in mMRC, CAT, CCQ, exacerbations and hospitalizations rates among the different groups (P < 0.001). Groups B and D had more severe airflow limitation than Groups A and C (P < 0.05). In the same groups with different severity of airflow limitation, the differences were mainly observed in body mass index, CAT, CCQ and treatment with long-acting muscarinic antagonist (LAMA) and LAMA + long-acting β2-agonist + inhaled corticosteroid (P < 0.05). After 18 months of follow-up, the exacerbations and hospitalizations rates were significantly different among different groups (P < 0.05). However, in the same groups with different airflow limitation severity, the mortality rates and number of exacerbations, hospitalizations and frequent exacerbators showed no differences. CONCLUSION: In the GOLD groups, different severity of airflow limitation had no impact on future exacerbations and mortality rate. It implies that pulmonary function is not a good indicator for predicting exacerbation. Dove 2021-05-20 /pmc/articles/PMC8143960/ /pubmed/34040367 http://dx.doi.org/10.2147/COPD.S309267 Text en © 2021 Song et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Song, Qing
Zhao, Yi-Yang
Zeng, Yu-Qin
Liu, Cong
Cheng, Wei
Deng, Min-Hua
Li, Xin
Ma, Li-Bing
Chen, Yan
Cai, Shan
Chen, Ping
The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title_full The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title_fullStr The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title_full_unstemmed The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title_short The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
title_sort characteristics of airflow limitation and future exacerbations in different gold groups of copd patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143960/
https://www.ncbi.nlm.nih.gov/pubmed/34040367
http://dx.doi.org/10.2147/COPD.S309267
work_keys_str_mv AT songqing thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT zhaoyiyang thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT zengyuqin thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT liucong thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chengwei thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT dengminhua thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT lixin thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT malibing thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chenyan thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT caishan thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chenping thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT songqing characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT zhaoyiyang characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT zengyuqin characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT liucong characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chengwei characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT dengminhua characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT lixin characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT malibing characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chenyan characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT caishan characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients
AT chenping characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients